Chryseriol attenuates the progression of OVA-induced asthma in mice through NF-κκB/HIF-1αα and MAPK/STAT1 pathways

Mo, Shangyao; Deng, Hao; Xie, Yuan; Yang, Lixia; Wen, L.

doi:10.15586/aei.v51i1.776

Cited by 8 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our research on mice with an induced asthma model using OVA administration, we observed severe pathological changes, including lung histological alterations, enriched BALF proteins, increased wet/dry ratio of lung tissues, and impaired lung function. These findings were consistent with previous studies [ 26 , 27 ]. However, after administering Arctiin, the pathological changes were markedly alleviated.…”

Section: Discussionsupporting

confidence: 94%

The protective effects of Arctiin in asthma by attenuating airway inflammation and inhibiting p38/NF-κB signaling

Yuan,

Sun

2024

Aging

View full text Add to dashboard Cite

Asthma is a common chronic inflammatory disease of the airways, which affects millions of people worldwide. Arctiin, a bioactive molecule derived from the traditional Chinese Burdock, has not been previously reported for its effects on asthma in infants. In this study, an asthma model was established in mice by stimulation with ovalbumin (OVA). Bronchoalveolar lavage (BALF) was collected from OVA-challenged mice and the cells were counted. Lung tissue was harvested for hematoxylin-eosin (HE) staining and measurement of Wet/Dry weight ratios. The expressions of proteins were detected using enzyme-linked immunosorbent assay (ELISA) and Western blots. The superoxide dismutase (SOD) activity in lung tissue was measured using a commercial kit. We found that Arctiin had beneficial effects on asthma treatment. Firstly, it attenuated OVA-challenged lung pathological alterations. Secondly, it ameliorated pro-inflammatory response by reducing the number of inflammatory cells and mitigating the imbalance of Th1/Th2 factors in the bronchoalveolar lavage (BALF) of OVA-challenged mice. Importantly, Arctiin ameliorated OVA-induced lung tissue impairment and improved lung function. Additionally, we observed that oxidative stress (OS) in the pulmonary tissue of OVA-challenged mice was ameliorated by Arctiin. Mechanistically, Arctiin prevented OVA-induced activation of p38 and nuclear factor-κB (NF-κB). Based on these findings, we conclude that Arctiin might serve as a promising agent for the treatment of asthma.

show abstract

Section: Discussionsupporting

confidence: 94%

The protective effects of Arctiin in asthma by attenuating airway inflammation and inhibiting p38/NF-κB signaling

Yuan,

Sun

2024

Aging

View full text Add to dashboard Cite

show abstract

“…The sensitizing doses utilized in current murine studies typically range from 10 to 100 μg 7,17–19 . However, the effects of various doses within this range have not been thoroughly investigated.…”

Section: Discussionmentioning

confidence: 99%

“…The sensitizing doses utilized in current murine studies typically range from 10 to 100 μg. 7 , 17 , 18 , 19 However, the effects of various doses within this range have not been thoroughly investigated. In 1999, Sakai et al 20 demonstrated the impact of sensitive OVA doses (0, 10, 100, and 1000 μg) on AHR; their study suggested that sensitization with a dose of 10 μg may be more effective than with a dose of 100 μg but almost completely inhibited at a dose of 1000 μg.…”

Section: Discussionmentioning

confidence: 99%

Effects of increasing sensitizing doses of ovalbumin on airway hyperresponsiveness in asthmatic mice

Chen,

Yuan,

Peng

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundThe dosage of ovalbumin (OVA) during the sensitization stage is considered a crucial factor in the development of airway hyperresponsiveness (AHR). However, the inconsistent dosages of sensitizing OVA used in current studies and the lack of research on their impact on AHR are notable limitations.MethodsWe examined the impact of increasing sensitizing doses of OVA in a murine asthma model, which entailed initial sensitization with OVA followed by repeated exposure to OVA aerosols. BALB/c mice were primed with doses of OVA (0, 10, 20, 50, and 100 μg) plus 1 mg Alum on Days 0 and 7, and were challenged with OVA aerosols (10 mg/mL for 30 min) between Days 14 and 17. Antigen‐induced AHR to methacholine (MCh), as well as histological changes, eosinophilic infiltration, and epithelial injury were assessed.ResultsThe result indicated that there are striking OVA dose‐related differences in antigen‐induced AHR to MCh. The most intense antigen‐induced AHR to MCh was observed with sensitization at 50 μg, while weaker responses were seen at 10, 20, and 100 μg. Meanwhile, there was a significant increase in eosinophil count with sensitization at 50 μg. The changes of AHR were correlated with total cells count, lymphocytes count, eosinophils count, and basophils count in bronchoalveolar lavage fluid; however, it did not correlate with histological changes such as cellular infiltration into bronchovascular bundles and goblet cell hyperplasia of the bronchial epithelium.ConclusionOverall, this study demonstrated that sensitization with 50 μg of OVA resulted in the most significant AHR compared to other dosages. These findings may offer valuable insights for future research on mouse asthma modeling protocols.

show abstract

“…[9] Simultaneously, chrysoeriol can slow down the progression of OVA-induced asthma in mice by inhibiting NF-κB/ HIF-1α and MAPK/STAT1 pathways, which is consistent with the GO enrichment results. [10] In the present research, the KEGG database was employed for pathway enrichment analysis. It was observed that within the simulated pathway, VEGFA and HIF-1α serve as crucial nodes in combating TNBC cell pathways.…”

Section: Discussionmentioning

confidence: 99%

Molecular mechanism of oroxyli semen against triple-negative breast cancer verified by bioinformatics and in vitro experiments

Chen,

Yang,

et al. 2023

Medicine

View full text Add to dashboard Cite

Objective: This study aimed to use network pharmacology to predict the therapeutic mechanism of oroxyli semen (OS) on triple-negative breast cancer (TNBC) and validate it through in vitro experiments. Methods: The active ingredients and target proteins of OS were retrieved from the Traditional Chinese Medicine Systems Pharmacology database, and the TNBC-related target genes were obtained from the GeneCards database. The overlapping genes were used to construct a protein–protein interaction (PPI) network via the String database. Furthermore, we employed an online bioinformatics analysis platform (https://www.bioinformatics.com.cn/) to perform gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses to evaluate biological processes, molecular functions, and cellular components and generate simulated signal pathways. Additionally, molecular docking was used to evaluate the binding ability of small molecule drugs and signaling pathway targets. CCK8 assay was conducted to detect the effect of small molecule drugs on TNBC cell viability, and Western Blot was utilized to verify the expression of AKT, VEGF, and hypoxia-inducible factor 1-alpha (HIF-1α) proteins. Results: Fifteen active ingredients and 166 therapeutic targets of OS were obtained from the Traditional Chinese Medicine Systems Pharmacology database. The Venn diagram revealed that 163 targets were related to TNBC. The protein–protein interaction network analysis identified AKT1, IL-6, JUN, vascular endothelial growth factor A (VEGFA), CASP3, and HIF-1α as potential core targets through which OS may treat TNBC. Furthermore, the molecular docking results indicated that the active ingredient chryseriol in OS had good binding ability with VEGFA, and HIF-1α. CCK8 assay results indicated that chryseriol inhibited the viability of MDA-MB-231 and BT-20 cells. Western Blot demonstrated that chryseriol intervention led to a decrease in VEGFA, and HIF-1α protein expression compared with the control group (P < .05), increased the cleaved PARP. Conclusion: OS may exert its therapeutic effects on TNBC through multiple cellular signaling pathways. Chryseriol, the active component of OS, can enhance the apoptosis of TNBC cells by targeting VEGFA/HIF-1α pathway. This study provided new insights into the potential therapeutic mechanism of OS for TNBC and may aid in the development of novel therapeutic approaches for TNBC.

show abstract

Chryseriol attenuates the progression of OVA-induced asthma in mice through NF-κκB/HIF-1αα and MAPK/STAT1 pathways

Cited by 8 publications

References 29 publications

The protective effects of Arctiin in asthma by attenuating airway inflammation and inhibiting p38/NF-κB signaling

The protective effects of Arctiin in asthma by attenuating airway inflammation and inhibiting p38/NF-κB signaling

Effects of increasing sensitizing doses of ovalbumin on airway hyperresponsiveness in asthmatic mice

Molecular mechanism of oroxyli semen against triple-negative breast cancer verified by bioinformatics and in vitro experiments

Contact Info

Product

Resources

About